Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement

Devendra Hiwase, David Ross, David Yeung, Agnes Yong, Steven Lane, Anna Brown, Chun Yew Fong, Timothy Hughes, John Reynolds, Daniel Thomas

Blood (2025) 146 (Supplement 1): 3855.

https://doi.org/10.1182/blood-2025-3855

Published: 2025

Journal Articles

High dose ascorbate downregulates innate immune cytokines in the bone marrow of TET2 mutant chronic myelomonocytic leukemia

Maha Kamel, Monika Kutyna, Nirmal Robinson, David Ross, David Yeung, Agnes Yong, Anna Brown, Timothy Hughes, Devendra Hiwase, Daniel Thomas

Blood (2025) 146 (Supplement 1): 2065.

https://doi.org/10.1182/blood-2025-2065

Published: 2025

Journal Articles

Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements

Yanjing Liu, Li Chai, Devendra Hiwase, David Ross, David Yeung, Agnes Yong, Steven Lane, Anna Brown, Chun Yew Fong, Timothy Hughes, John Reynolds, Daniel Thomas, Daniel Tenen, Mahmoud Bassal

Blood (2025) 146 (Supplement 1): 3231.

https://doi.org/10.1182/blood-2025-3231

Published: 2025

Journal Articles

Secondary Acute Myeloid Leukemia transformed from chronic myelomonocytic leukemia is strongly resistant to venetoclax but demonstrates sensitivity to anti-GM-CSF lenzilumab immunotherapy

Kelly Lim, Monika Kutyna, Akash Kalro, Devendra Hiwase, Daniel Thomas

Blood (2025) 146 (Supplement 1): 1714.

https://doi.org/10.1182/blood-2025-1714

Published: 2025

Journal Articles

TGF-β regulates CD123 and chemotherapy resistance in Acute Myeloid Leukemia stem cells

Sepideh Azizi Taramsary, Jo Woodcock, Hosein Anani, Denis Tvorogov, Angel Lopez, Daniel Thomas

Blood (2025) 146 (Supplement 1): 1713.

https://doi.org/10.1182/blood-2025-1713

Published: 2025

Journal Articles

TP53 -Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Kevin Hung, Aref Al-Kali, Carla Toop, Mrinal M. Patnaik, Zoe Price, Taxiarchis Kourelis, Daniel Thomas, Morie A. Gertz, Hossein Anani, Wilson I. Gonsalves, Chung Hoow Kok, Ayalew Tefferi, Devendra Hiwase, Mithun V Shah

Blood (2024) 144 (Supplement 1): 4594.

https://doi.org/10.1182/blood-2024-211931

Published: 2024

Journal Articles

Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS

Thomas Wiseman, Michaela Spooner, Shreyas Khanna, Kevin Hung, Carla Toop, Deepak Singhal, David M Ross, David T Yeung, Anna Brown, Hamish S Scott, Christopher N. Hahn, Daniel Thomas, Chung How Kok, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 3208.

https://doi.org/10.1182/blood-2024-209123

Published: 2024

Journal Articles

Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections (URTIs) and Venous Thromboembolism (VTE) in Patients with Multiple Myeloma Treated with Isatuximab

Daniel Thomas Jones, Hazem Aboaid, Ramaditya Srinivasmurthy, Kevin Nguyen, Rishi Kumar Nanda, Kyaw Zin Thein, Thura Win Htut

Blood (2024) 144 (Supplement 1): 2390.

https://doi.org/10.1182/blood-2024-211295

Published: 2024

Journal Articles

Efficacy of Isatuximab Combination Regimens in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Hazem Aboaid, Ramaditya Srinivasmurthy, Daniel Thomas Jones, Kevin Nguyen, Rishi Kumar Nanda, Kyaw Zin Thein, Thura Win Htut

Blood (2024) 144 (Supplement 1): 7036.

https://doi.org/10.1182/blood-2024-209018

Published: 2024

Journal Articles

Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Second Primary Malignancies (SPMs) in Patients with Multiple Myeloma (MM) Treated with Isatuximab

Hazem Aboaid, Kevin Nguyen, Daniel Thomas Jones, Ramaditya Srinivasmurthy, Rishi Kumar Nanda, Kyaw Zin Thein, Thura Win Htut

Blood (2024) 144 (Supplement 1): 7866.

https://doi.org/10.1182/blood-2024-211236

Published: 2024

Journal Articles

High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies

Shreyas Khanna, Harini Haran, Thomas Wiseman, Kevin Hung, Aidan Sapio, Philip Selby, Michaela Spooner, David T Yeung, Daniel Thomas, Chung How Kok, Andrew H Wei, Chong Chyn Chua, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 4237.

https://doi.org/10.1182/blood-2024-209258

Published: 2024

Journal Articles

Evidence-Based Risk Stratification of TP53 -Mutated Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 3213.

https://doi.org/10.1182/blood-2024-198269

Published: 2024

Journal Articles

High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine

Maha M Kamel, Nirmal Robinson, Monika Kutyna, Kelly Lim, Chloe Thompson-Peach, Steven W Lane, David T Yeung, Agnes S. M. Yong, David M Ross, Devendra Hiwase, Daniel Thomas

Blood (2024) 144 (Supplement 1): 1817.

https://doi.org/10.1182/blood-2024-204177

Published: 2024

Journal Articles

CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Kelly Lim, Monika Kutyna, Winnie Kan, Angel F. Lopez, Anna Brown, Agnes S. M. Yong, Steven W Lane, Chun Yew Fong, Timothy P Hughes, David T Yeung, David M Ross, Devendra Hiwase, Daniel Thomas

Blood (2024) 144 (Supplement 1): 3196.

https://doi.org/10.1182/blood-2024-202682

Published: 2024

Journal Articles

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

Devendra Hiwase, David M Ross, David T Yeung, Agnes S. M. Yong, Steven W Lane, Anna Brown, Chun Yew Fong, Timothy P Hughes, John Reynolds, Daniel Thomas

Blood (2024) 144 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2024-202867

Published: 2024

Journal Articles

Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity

Ilaria Stefania Pagani, Vaidehi Krishnan, John Ouyang, Chung How Kok, BeiJun Chen, Elyse C Page, Phuong Dang, Verity A Saunders, Jane James, Kelly Lim, Naranie Shanmuganathan, Susan Branford, Charles Chuah, David T Yeung, Daniel Thomas, Timothy P Hughes, Sin Tiong Ong, David M Ross

Blood (2024) 144 (Supplement 1): 2715.

https://doi.org/10.1182/blood-2024-206591

Published: 2024

Journal Articles

Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia

Thomas Wiseman, Michaela Spooner, Shreyas Khanna, Kevin Hung, Carla Toop, Deepak Singhal, David T Yeung, Hamish S Scott, Christopher N. Hahn, Daniel Thomas, Chung How Kok, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 1267.

https://doi.org/10.1182/blood-2024-212120

Published: 2024

Journal Articles

Impact of Chronic Inflammation and Cytotoxic Therapy on Bone Marrow Microenvironment of Patients with Autoimmune Rheumatic Diseases and Myeloid Neoplasms

Monika Kutyna, Daniel Thomas, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 1304.

https://doi.org/10.1182/blood-2024-212301

Published: 2024

Journal Articles

Transforming Growth Factor Beta 1/SMAD2 Signalling Axis Regulates Leukemia Stem Cell Marker CD123: Implications for Acute Myeloid Leukemia

Sepideh Azizi Taramsary, Joanna Woodcock, Denis Tvorogov, Angel F. Lopez, Daniel Thomas

Blood (2024) 144 (Supplement 1): 5723.

https://doi.org/10.1182/blood-2024-204191

Published: 2024

Journal Articles

IDH -mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Blood (2024) 143 (18): 1873–1877.

https://doi.org/10.1182/blood.2023023593

Published: 2024

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement

High dose ascorbate downregulates innate immune cytokines in the bone marrow of TET2 mutant chronic myelomonocytic leukemia

Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements

Secondary Acute Myeloid Leukemia transformed from chronic myelomonocytic leukemia is strongly resistant to venetoclax but demonstrates sensitivity to anti-GM-CSF lenzilumab immunotherapy

TGF-β regulates CD123 and chemotherapy resistance in Acute Myeloid Leukemia stem cells

TP53 -Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS

Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections (URTIs) and Venous Thromboembolism (VTE) in Patients with Multiple Myeloma Treated with Isatuximab

Efficacy of Isatuximab Combination Regimens in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Second Primary Malignancies (SPMs) in Patients with Multiple Myeloma (MM) Treated with Isatuximab

High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies

Evidence-Based Risk Stratification of TP53 -Mutated Myeloid Neoplasms

High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine

CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity

Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia

Impact of Chronic Inflammation and Cytotoxic Therapy on Bone Marrow Microenvironment of Patients with Autoimmune Rheumatic Diseases and Myeloid Neoplasms

Transforming Growth Factor Beta 1/SMAD2 Signalling Axis Regulates Leukemia Stem Cell Marker CD123: Implications for Acute Myeloid Leukemia

IDH -mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only